DGM
Darwin Global Management Portfolio holdings
AUM
$2.38B
This Quarter Return
+13.89%
1 Year Return
+81.43%
3 Year Return
+6,053.69%
5 Year Return
–
10 Year Return
–
AUM
$110M
AUM Growth
+$110M
(-83%)
Cap. Flow
-$548M
Cap. Flow
% of AUM
-497.56%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
13
New
–
Increased
1
Reduced
–
Closed
12
Top Buys
| 1 |
AstraZeneca
AZN
|
$76.3M |
Top Sells
| 1 |
Pfizer
PFE
|
$455M |
| 2 |
Intellia Therapeutics
NTLA
|
$71.6M |
| 3 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$25.9M |
| 4 |
BioNTech
BNTX
|
$23.2M |
| 5 |
Enanta Pharmaceuticals
ENTA
|
$12.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AstraZeneca
AZN
$248B
| $110M | 100% | 1,661,684 +1,149,776 | +225% | +$76.3M |
|
2
Fate Therapeutics
FATE
$120M
| – | – | -153,537 | Closed | -$8.98M |
|
3
Fulcrum Therapeutics
FULC
$351M
| – | – | -317,428 | Closed | -$5.62M |
|
4
Keros Therapeutics
KROS
$618M
| – | – | -111,500 | Closed | -$6.52M |
|
|
5
Intellia Therapeutics
NTLA
$1.22B
| – | – | -605,587 | Closed | -$71.6M |
|
|
6
Pfizer
PFE
$141B
| – | – | -7,697,762 | Closed | -$455M |
|
|
VERV
7
DELISTED
Verve Therapeutics
VERV
| – | – | -23,104 | Closed | -$852K |
|
8
Vir Biotechnology
VIR
$686M
| – | – | -145,841 | Closed | -$6.11M |
|
|
CCXI
9
DELISTED
ChemoCentryx, Inc.
CCXI
| – | – | -161,802 | Closed | -$5.89M |
|
|
INBX
10
DELISTED
Inhibrx, Inc. Common Stock
INBX
| – | – | -591,975 | Closed | -$25.9M |
|
11
Aclaris Therapeutics
ACRS
$209M
| – | – | -216,143 | Closed | -$3.14M |
|
|
12
BioNTech
BNTX
$24B
| – | – | -90,057 | Closed | -$23.2M |
|
|
13
Enanta Pharmaceuticals
ENTA
$180M
| – | – | -166,190 | Closed | -$12.4M |
|